GRAIL, Inc. (NASDAQ:GRAL) traded at around $133 on October 7, down 3.19% on the day, though still 93.00% higher over twelve months. Guardant Health, Inc. (NASDAQ:GH) traded near $168 over the same session, up 161.55% across the year.
Both sell blood tests that look for cancer, and one of them has seven times the revenue of the other.
READ ALSO: What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing?
The Revenue Gap Is the Comparison:
Guardant Health produced $1.18 billion of trailing revenue against $165.26 million at Grail. That is not a difference of degree between two development-stage companies. It is a commercial business beside a pre-commercial one. The margins follow. Gross margin is 65.01% at Guardant Health against 49.71% at Grail.
The operating lines are where the gap becomes severe. Operating margin is negative 38.25% at Guardant Health and negative 332.00% at Grail. Spending more than four dollars for every dollar of revenue is what a company looks like before reimbursement arrives.
Growth favors the larger one as well, at 44.30% revenue growth against 25.70%. In January, we ranked ten stocks for high returns. The one we put first has returned almost 30% since.
The Balance Sheets Point the Other Way:
Grail holds $861.61 million of cash against $91.31 million of debt. Guardant Health holds $1.05 billion of cash against $1.70 billion of debt.
Book value per share is negative $1.67 at Guardant Health, which means liabilities exceed assets on the stated accounts. So the company with the real revenue has funded it by borrowing, and the company without revenue has not had to.
Cash burn is comparable in absolute terms. Free cash flow was negative $296.16 million at Grail against negative $240.72 million. Gross margin at Grail is 49.71%, so roughly half of each test sold still covers something other than the cost of running it.
Grail can fund roughly three more years at that rate from cash on hand, which is the one advantage of having spent less. In May we ranked this year’s best dividend performers. The one that finished first has since fallen 38%.
The Valuation Case:
Grail traded at around $133 on October 7 and is worth $5.94 billion, against $22.59 billion for Guardant Health. Sustainability for both depends on insurance reimbursement rather than on clinical evidence, since neither test is widely covered yet.
Neither company has a trailing earnings multiple, because neither has earnings. On sales, the valuations diverge sharply, at 35.92 times for Grail against 19.09 for Guardant Health. Short interest of 19.48% of the float at Grail against 8.56% shows where the doubt is concentrated.
Conclusion:
Guardant Health is the better business and the cheaper stock on every operating measure. A 65.01% gross margin, $1.18 billion of revenue growing 44.30%, and an operating loss of 38.25% are all clear advantages over Grail. However, it carries $1.70 billion of debt against a negative book value of $1.67 a share. Grail holds $861.61 million of cash against $91.31 million of debt at a third of the market value. The number to watch is operating margin at Grail, because negative 332.00% is the distance it has to travel before the revenue matters.
Market Sentiment:
GRAIL, Inc. was held by 29 hedge funds with a combined stake value of about $1.06 billion at the end of Q2 2026 in the Insider Monkey database. This is down from 33 hedge fund holders with a cumulative investment value of around $0.77 billion in the previous quarter.
Guardant Health, Inc. was held by 80 hedge funds with a combined stake value of about $3.55 billion at the end of Q2 2026 in the Insider Monkey database. This is up from 58 hedge fund holders with a cumulative investment value of around $2.00 billion in the previous quarter.
While we acknowledge the risk and potential of GRAL and GH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GRAL and GH and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Here is Why Tripadvisor (TRIP) is a Bad Investment at Today’s Price and What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center